Please use this identifier to cite or link to this item:
Title: Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial
Authors: Hristova, Ivalina;Boellaard, Ronald;Vogel, Wouter;Mottaghy, Felix;Marreaud, Sandrine;Collette, Sandra;Schöffski, Patrick;Sanfilippo, Roberta;Dewji, Raz;van der Graaf, Winette;Oyen, Wim J G
Year: May-2015
Abstract: (18)F-Labelled fluorodeoxyglucose (FDG) can detect early changes in tumour metabolism and may be a useful quantitative imaging biomarker (QIB) for prediction of disease stabilization, response and duration of progression-free survival (PFS). Standardization of imaging procedures is a prerequisite, especially in multicentre clinical trials. In this study we reviewed the quality of FDG scans and compliance with the imaging guideline (IG) in a phase III clinical trial.
ISSN: 10.1007/s00259-015-3002-0
Appears in Collections:European Journal Of nuclear medicine _ molecular Imaging 2015

Files in This Item:
File Description SizeFormat 
848.pdf657.09 kBAdobe PDFThumbnail
Download    Request a copy

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.